Clinical trialsCompany release

UCB: Bimekizumab keeps numerical ACR50 lead over risankizumab at Week 24 in BE BOLD

UCB · Mon 09 Nov 2026

Week 24 data from the head-to-head psoriatic arthritis study show 54.9% of bimekizumab-bkzx patients reaching ACR50 versus 43.8% on risankizumab, with no new safety signals.

UCB has reported Week 24 results from BE BOLD, a head-to-head study comparing bimekizumab-bkzx with risankizumab in adults with active psoriatic arthritis. The data were presented at ACR Convergence 2026 on 9 November 2026.

At Week 24, 54.9% of patients on bimekizumab-bkzx achieved an ACR50 response, against 43.8% of those on risankizumab. ACR50 denotes a 50% improvement in the American College of Rheumatology response criteria. The result builds on the statistically significant Week 16 primary endpoint outcome.

Secondary endpoints also favoured bimekizumab-bkzx numerically, but the differences were not statistically significant. The summary available does not give further detail on those endpoints.

On safety, UCB reported no new signals. Candida infections were more frequent with bimekizumab-bkzx than with risankizumab, at 2.9% versus 0.7%, and all were mild or moderate.

What it means for your team

  • The Week 24 ACR50 gap is numerical; significance was established only for the Week 16 primary endpoint, so claims should be framed carefully.
  • Pharmacovigilance teams may note the higher Candida infection rate with bimekizumab-bkzx (2.9% vs 0.7%), all mild or moderate, as part of the comparative safety profile.
  • Market-access teams may use head-to-head data in dossiers, but should note that secondary endpoint differences did not reach statistical significance.

Company's press release: UCB ↗

Article written by VigiEye from the official source (UCB). Claims are the company's own. AI-assisted; check the source before acting.

More Clinical trials All →